StemCyte
1997
FOUNDED
PRIVATE
STATUS
201-300
EMPLOYEES
Later Stage VC
LATEST DEAL TYPE
9
INVESTORS
Description
Developer of regenerative cell therapy (RCT) technologies, focusing on stem cell transplantation and regenerative medicine by using a proprietary platform mononuclear cell (MNC) technology derived from its large and genetically diverse donor cord blood stem cell bank. The company's proprietary platform MNC technology aims to apply the treatment to neurologic diseases such as Spinal Cord Injury, Stroke, Parkinson's Disease, Macular Degeneration and Alzheimer's disease.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Biotechnology
Other Devices and Supplies
Primary Office
- 13800 Live Oak Avenue
- Baldwin Park, CA 91706
- United States
+1 (626) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore StemCyte’s full profile, request a free trial.
StemCyte Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC | 000.00 | Completed | Generating Revenue | |||
| 9. Secondary Transaction - Private | 000.00 | Completed | Generating Revenue | |||
| 8. Debt - General | 23-Nov-2010 | 000.00 | Completed | Generating Revenue | ||
| 7. Debt - General | 01-Jun-2009 | 000 | 000.00 | Completed | Generating Revenue | |
| 6. Convertible Debt | 02-Oct-2007 | 00.000 | 000.00 | Completed | Generating Revenue | |
| 5. Later Stage VC (Series 3) | 14-Jul-2006 | 00.00 | 000.00 | Completed | Generating Revenue | |
| 4. Later Stage VC (Series D) | 20-May-2002 | 00.000 | 000.00 | 0000 | Completed | Startup |
| 3. Later Stage VC (Series C) | 14-Feb-2002 | 00.00 | 000.00 | 00000 | Completed | Startup |
| 2. Early Stage VC (Series B) | 02-Oct-2000 | $5.46M | $5.46M | 000.00 | Completed | Startup |
| 1. Early Stage VC (Series A) | Completed | Startup |
StemCyte Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | 0,000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 00.000 |
| Series C | 000,000 | 00.000000 | 00 | 000 | 000 | 00 | 00.00 | 0.000 |
| Series B | 1,821,000 | $0.001000 | 7% | $3 | $3 | 1x | $2.5 | 11.51% |
| Series A | 1,850,000 | $0.001000 | 7% | $2.5 | $2.5 | 1x | $1 | 24.36% |
StemCyte Competitors (1)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| 00000000 000000000 | Venture Capital-Backed | Chennai, India | 0000 | 00.00 | 0000000000 0 | 00.00 |
StemCyte Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Amkey Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Fairbridge Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Kenson Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Kuwait Life Sciences Company | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Montage Capital | Mezzanine | Minority | 000 0000 | 000000 0 |
StemCyte Executive Team (8)
2 Former Executives
You’re viewing 5 of 8 executives. Get the full list »StemCyte Board Members (7)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| George Lee Ph.D | Amkey Ventures | Board Member | 000 0000 | |
| Jonas Wang Ph.D | StemCyte | Chief Executive Officer, President & Chairman | 000 0000 | |
| Kenneth Giacin | StemCyte | Vice Chairman & Chief Strategy Officer | 000 0000 | |
| Lawrence Petz MD | StemCyte | Chief Medical Officer & Chairman of Medical Advisory Board | 000 0000 | |
| MeiAnn Liu | Self | Board Member | 000 0000 |
2 Former Board Members
You’re viewing 5 of 7 board members. Get the full list »